Blood Pressure Control in Patients with Diabetic Kidney Disease

the Korean Diabetic Kidney Disease Working Group

doi:10.5049/EBP.2022.20.2.39

Blood Pressure Control in Patients with Diabetic Kidney Disease

the Korean Diabetic Kidney Disease Working Group

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease. Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested the implementation of a more intensive BP control with a target systolic BP (SBP) of <120 mmHg based on the evidence that the CV benefits obtained is outweighed by the kidney injury risk associated with a lower BP target. However, an extremely low BP level may paradoxically aggravate renal function and CV outcomes. Herein, we aimed to review the existing literature regarding optimal BP control using medications for DKD.

Original language	English
Pages (from-to)	39-48
Number of pages	10
Journal	Electrolyte and Blood Pressure
Volume	20
Issue number	2
DOIs	https://doi.org/10.5049/EBP.2022.20.2.39
State	Published - 2022

Bibliographical note

Publisher Copyright:
© 2022 Korean Society for Electrolyte and Blood Pressure Research.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Blood pressure
Diabetes
Kidney
Mortality

Access to Document

10.5049/EBP.2022.20.2.39

Cite this

@article{36141442645b4eb59a5feb7b61e2a8d4,

title = "Blood Pressure Control in Patients with Diabetic Kidney Disease",

abstract = "Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease. Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested the implementation of a more intensive BP control with a target systolic BP (SBP) of <120 mmHg based on the evidence that the CV benefits obtained is outweighed by the kidney injury risk associated with a lower BP target. However, an extremely low BP level may paradoxically aggravate renal function and CV outcomes. Herein, we aimed to review the existing literature regarding optimal BP control using medications for DKD.",

keywords = "Blood pressure, Diabetes, Kidney, Mortality",

author = "\{the Korean Diabetic Kidney Disease Working Group\} and Yaeni Kim and Won Kim and Kim, \{Jwa Kyung\} and Moon, \{Ju Young\} and Samel Park and Park, \{Cheol Whee\} and Park, \{Hoon Suk\} and Song, \{Sang Heon\} and Yoo, \{Tae Hyun\} and Lee, \{So Young\} and Lee, \{Eun Young\} and Jeonghwan Lee and Kyubok Jin and Cha, \{Dae Ryong\} and Cha, \{Jin Joo\} and Han, \{Sang Youb\}",

note = "Publisher Copyright: {\textcopyright} 2022 Korean Society for Electrolyte and Blood Pressure Research.",

year = "2022",

doi = "10.5049/EBP.2022.20.2.39",

language = "English",

volume = "20",

pages = "39--48",

journal = "Electrolyte and Blood Pressure",

issn = "1738-5997",

publisher = "Korean Society of Electrolyte and Blood Pressure Research",

number = "2",

}

TY - JOUR

T1 - Blood Pressure Control in Patients with Diabetic Kidney Disease

AU - the Korean Diabetic Kidney Disease Working Group

AU - Kim, Yaeni

AU - Kim, Won

AU - Kim, Jwa Kyung

AU - Moon, Ju Young

AU - Park, Samel

AU - Park, Cheol Whee

AU - Park, Hoon Suk

AU - Song, Sang Heon

AU - Yoo, Tae Hyun

AU - Lee, So Young

AU - Lee, Eun Young

AU - Lee, Jeonghwan

AU - Jin, Kyubok

AU - Cha, Dae Ryong

AU - Cha, Jin Joo

AU - Han, Sang Youb

PY - 2022

Y1 - 2022

N2 - Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease. Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested the implementation of a more intensive BP control with a target systolic BP (SBP) of <120 mmHg based on the evidence that the CV benefits obtained is outweighed by the kidney injury risk associated with a lower BP target. However, an extremely low BP level may paradoxically aggravate renal function and CV outcomes. Herein, we aimed to review the existing literature regarding optimal BP control using medications for DKD.

AB - Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease. Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested the implementation of a more intensive BP control with a target systolic BP (SBP) of <120 mmHg based on the evidence that the CV benefits obtained is outweighed by the kidney injury risk associated with a lower BP target. However, an extremely low BP level may paradoxically aggravate renal function and CV outcomes. Herein, we aimed to review the existing literature regarding optimal BP control using medications for DKD.

KW - Blood pressure

KW - Diabetes

KW - Kidney

KW - Mortality

UR - https://www.scopus.com/pages/publications/85148362389

U2 - 10.5049/EBP.2022.20.2.39

DO - 10.5049/EBP.2022.20.2.39

M3 - Article

AN - SCOPUS:85148362389

SN - 1738-5997

VL - 20

SP - 39

EP - 48

JO - Electrolyte and Blood Pressure

JF - Electrolyte and Blood Pressure

IS - 2

ER -

Blood Pressure Control in Patients with Diabetic Kidney Disease

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this